Targeting Covid-19 with a Therapeutic Interfering Particle

摘要 由SARS-CoV-2引起的新冠肺炎大流行目前 世界上最严重的公共卫生危机。考虑到这种疾病前所未有的范围，它是至关重要的 探索缓解这场危机的新策略。Aleph Treateutics和UCSF联合开发了eTIP1， 一种治疗性干扰粒子。ETIP1是在DARPA资助的计划下开发的，并显示出强大的 肠道病毒(脊髓灰质炎病毒1型和3型、EVA71和柯萨奇病毒B3)也具有广谱活性 作为呼吸道病毒EV-D68/HRV-87，鼻病毒A16和A1B，以及甲型流感，最近我们已经展示了 ETIP1显著抑制SARS-CoV-2在细胞培养和K18-ACE2小鼠体内的复制。vt.给出 因此，对eTIP1作为一种潜在的抗SARS-CoV-2药物进行全面评估是至关重要的。这部作品 可能是针对SARS-CoV-2的潜在治疗或预防性药物的起点。这也将是 代表着广谱抗病毒药物开发的重大突破，该药物可以 潜在地瞄准当前和未来的病毒威胁。

SUMMARY The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA-funded program and shows potent broad-spectrum activity across enteroviruses (Poliovirus Type 1 and 3, EVA71, and Coxsackievirus B3) as well as respiratory viruses EV-D68/HRV-87, Rhinovirus A16 and A1B, and Influenza A. Recently we have shown that eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice. Given these results, it is critical to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. This work could be the starting point for a potential therapy or prophylactic agent against SARS-CoV-2. This would also represent a significant breakthrough for the development of a broad-spectrum antiviral agent that could potentially target current and future viral threats.